Lipid Disorders and Metabolic-Associated Fatty Liver Disease

• Shima Dowla Anwar ^[1] ; Christy Foster ^[2] ; Ambika Ashraf ^[2]
  1. [1] Harvard Medical School

     Harvard Medical School

     City of Boston, Estados Unidos

     
  2. [2] University of Alabama at Birmingham

     University of Alabama at Birmingham

     Estados Unidos

     
• Localización: Endocrinology and metabolism clinics of North America, ISSN 0889-8529, Vol. 52, Nº. 3, 2023, págs. 445-457
• Idioma: inglés
• Enlaces
  • Texto completo
• Resumen

  • Dyslipidemia has been linked metabolic-associated fatty liver disease (MAFLD). Several genes and transcription factors involved in lipid metabolism can increase susceptibility to MAFLD. Multiple parallel 'hits' have been proposed for developing hepatic steatosis, NASH, and MAFLD, including insulin resistance and subsequent free fatty acid excess, de novo lipogenesis, and excessive hepatic triglyceride and cholesterol deposition in the liver. This lead to defective beta-oxidation in the mitochondria and VLDL export and increased inflammation. Given the significant cardiovascular risk, dyslipidemia associated with MAFLD should be managed by lifestyle changes and lipid-lowering agents such as statins, fenofibrate, and omega-3 fatty acids, with judicious use of insulin-sensitizing agents, and adequate control of dysglycemia.